Search
Vardenafil
go.drugbank.com/drugs/DB00862ApprovedCompared to [sildenafil] and [tadalafil], vardenafil is a more potent inhibitor of PDE5; however, its selectivity for other PDE isoforms is lower than the one detected for tadalafil. … Although other PDE5 inhibitors such as [sildenafil] and [tadalafil] have been associated with rare cases of acute liver injury, the use of vardenafil has not been linked to hepatotoxic effects.
Lancovutide
go.drugbank.com/drugs/DB05029InvestigationalLancovutide is a 19-amino-acid tetracyclic peptide produced by Streptoverticillium cinnamoneus and is closely related to cinnamycin (Ro09-0198). It belongs to the lantibiotics. … Lantibiotics are bacteriocins that are characterized by the presence of a high proportion of unusual amino acids.
Diethylstilbestrol
go.drugbank.com/drugs/DB00255ApprovedWithdrawnAccording to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), diethylstilbestrol has been listed as a known carcinogen.
Nandrolone decanoate
go.drugbank.com/drugs/DB08804ApprovedIllicitInvestigationalL32564,L9464] The process for creating esters of [nandrolone] was patented in Spain in 1959[L33244] and in 1960, it was described as having a long duration of action and strong anabolic effect compared to
Eplontersen
go.drugbank.com/drugs/DB16199ApprovedInvestigational[A262975] Hereditary transthyretin-mediated amyloidosis is caused primarily by pathogenic variants of the TTR gene, leading to the formation and thus accumulation of insoluble and misfolded amyloid in … multiple organs, although wild-type misfolded TTR has also been observed to contribute to the disease pathophysiology.
Rimonabant
go.drugbank.com/drugs/DB06155ApprovedWithdrawnRimonabant is the first selective CB1 receptor blocker to be approved for use anywhere in the world. Rimonabant is approved in 38 countries including the E.U., Mexico, and Brazil. … Rimonabant is an anorectic anti-obesity drug produced and marketed by Sanofi-Aventis. It is an inverse agonist for the cannabinoid receptor CB1. Its main avenue of effect is reduction in appetite.
Toripalimab
go.drugbank.com/drugs/DB15043ApprovedInvestigationalOne mechanism by which this occurs is through the overexpression of programmed cell death ligand (PD-L1)[A261506] - the binding of PD-L1 (and PD-L2) to its target receptor (PD-1) results in the inhibition … The proliferation of some cancers can be attributed, at least in part, to the suppression of host tumor surveillance.
Apalutamide
go.drugbank.com/drugs/DB11901ApprovedInvestigationalApalutamide was approved in February 2018 by the FDA as Erleada for the treatment of patients with non-metastatic prostate cancer that is resistant to treatment with hormone therapy (castration-resistant … Approximately 10 to 20 % of prostate cancer cases are castration-resistant, and up to 16% of these patients show no evidence of cancer metastasis at the time of castration-resistant diagnosis [L1295].
Dapoxetine
go.drugbank.com/drugs/DB04884InvestigationalIn a phase II proof-of-concept study conducted by PPD, dapoxetine demonstrated a statistically significant increase in ejaculatory latency when compared to placebo. … In October 2005, the company received a FDA Non-Approvable letter from the FDA, at which time they planned to work with regulators to address outstanding questions.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeDolasetron
go.drugbank.com/drugs/DB00757ApprovedInvestigationalThis drug is not shown to have activity at other known serotonin receptors, and has low affinity for dopamine receptors.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome